Patents by Inventor Roger D. Tung

Roger D. Tung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4-hydroxybutyric acid analogs
    Patent number: 11939285
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: March 26, 2024
    Assignee: SUN PHARMACEUTICAL INDUSTRIES, INC.
    Inventor: Roger D. Tung
  • DEUTERATED ANALOGS OF D-SERINE AND USES THEREOF
    Publication number: 20220313640
    Abstract: This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
    Type: Application
    Filed: May 29, 2020
    Publication date: October 6, 2022
    Inventors: Dario Doller, Christopher L. Brummel, Julie F. Liu, Roger D. Tung, Darren H. Wong, Tracey L. Petryshen, Raymond S. Hurst
  • 4-HYDROXYBUTYRIC ACID ANALOGS
    Publication number: 20220162146
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: October 29, 2021
    Publication date: May 26, 2022
    Inventor: Roger D. Tung
  • 4-HYDROXYBUTYRIC ACID ANALOGS
    Publication number: 20210403407
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: February 1, 2021
    Publication date: December 30, 2021
    Inventors: Roger D. Tung, Adam J. Morgan
  • 4-hydroxybutyric acid analogs
    Patent number: 11161798
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: November 2, 2021
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • DEUTERATED ANALOGS OF D-BETA-HYDROXYBUTYRIC ACID AND USES THEREOF
    Publication number: 20210008018
    Abstract: This disclosure relates to deuterated D-?-hydroxybutyric acid (DBHB) of Formula I: wherein each of the variables are defined herein, and pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 14, 2021
    Inventors: Roger D. Tung, I. Robert Silverman, Naeem Yusuff
  • DEUTERATED ANALOGS OF D-SERINE AND USES THEREOF
    Publication number: 20200390732
    Abstract: This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
    Type: Application
    Filed: May 27, 2020
    Publication date: December 17, 2020
    Inventors: Dario Doller, Christopher L. Brummel, Julie F. Liu, Roger D. Tung
  • 4-HYDROXYBUTYRIC ACID ANALOGS
    Publication number: 20200385330
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Application
    Filed: January 10, 2020
    Publication date: December 10, 2020
    Applicant: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • DEUTERATED ANALOGS OF D-SERINE AND USES THEREOF
    Publication number: 20200368193
    Abstract: This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
    Type: Application
    Filed: November 21, 2018
    Publication date: November 26, 2020
    Inventors: Dario Doller, Christopher L. Brummel, Julie F. Liu, Roger D. Tung
  • Deuterated baricitinib
    Patent number: 10842792
    Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification, as well as pharmaceutical compositions comprising the same, and methods of using such compounds and compositions to inhibit at least one of Janus Kinase-1 and -2 and diseases associated with those kinases.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: November 24, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Deuterated idebenone
    Patent number: 10843993
    Abstract: The present invention in one embodiment provides a method of treating Leber's hereditary optic neuropathy, comprising administering to a subject in need of such treatment a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: November 24, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • Deuterated CFTR potentiators
    Patent number: 10759721
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein each X and each R is defined within. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: September 1, 2020
    Assignee: Vertex Pharmaceuticals (Europe) Limited
    Inventors: Adam J. Morgan, Roger D. Tung
  • Deuterated CFTR modulators
    Patent number: 10738036
    Abstract: This invention relates to novel, deuterated forms of VX-661 and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating cystic fibrosis.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: August 11, 2020
    Assignee: Vertex Pharmaceuticals (Europe) Limited
    Inventors: I. Robert Silverman, Roger D. Tung
  • Deuterated analogs of D-serine and uses thereof
    Patent number: 10668036
    Abstract: This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: June 2, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Dario Doller, Christopher L. Brummel, Julie F. Liu, Roger D. Tung
  • DEUTERATED CFTR POTENTIATORS
    Publication number: 20200031776
    Abstract: This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein each X and each R is defined within. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.
    Type: Application
    Filed: September 23, 2016
    Publication date: January 30, 2020
    Inventors: Adam J. Morgan, Roger D. Tung
  • 4-hydroxybutyric acid analogs
    Patent number: 10532971
    Abstract: This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: January 14, 2020
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung
  • DEUTERATED IDEBENONE
    Publication number: 20190367438
    Abstract: The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.
    Type: Application
    Filed: May 16, 2019
    Publication date: December 5, 2019
    Inventor: Roger D. Tung
  • DEUTERATED MORPHINAN COMPOUNDS FOR TREATING AGITATION
    Publication number: 20190336494
    Abstract: This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disorders with such a morphinan compound in combination with quinidine, or pharmaceutically acceptable salt of either or both thereof.
    Type: Application
    Filed: July 22, 2019
    Publication date: November 7, 2019
    Inventors: Roger D. Tung, Philip B. Graham
  • DEUTERATED ANALOGS OF D-SERINE AND USES THEREOF
    Publication number: 20190328692
    Abstract: This disclosure relates to deuterated D-serine, pharmaceutically acceptable salts thereof, analogs and prodrugs thereof, pharmaceutical compositions thereof, and methods of use.
    Type: Application
    Filed: July 2, 2019
    Publication date: October 31, 2019
    Inventors: Dario Doller, Christopher L. Brummel, Julie F. Liu, Roger D. Tung
  • Deuterated GFT-505
    Patent number: 10442761
    Abstract: This invention relates to novel deuterated forms of GFT-505, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are characterized by reduced PPAR-alpha and/or PPAR-delta activity.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 15, 2019
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Roger D. Tung